DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
RISLENEMDAZ
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
RISLENEMDAZ
×
Maximum Phase:
2
First Approval:
None
UNII:
5HAM167S5T
Molecule Type:
Small molecule
Molecular Formula:
C19H23FN4O2
Molecular Weight:
358.42
AlogP:
3.19
PSA:
67.35
HBD:
1.0
HBA:
#RotB:
5.0
Source:
TEZAMPANEL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Glutamate receptor ionotropic AMPA antagonist
TEZAMPANEL
×
Maximum Phase:
2
First Approval:
None
UNII:
6XN50U405Y
Molecule Type:
Small molecule
Molecular Formula:
C13H21N5O2
Molecular Weight:
279.34
AlogP:
0.61
PSA:
103.79
HBD:
3.0
HBA:
#RotB:
4.0
Source:
DM-CHOC-PEN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DM-CHOC-PEN
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CGC-11047
2
Small molecule
Investigational
Unknown
Unknown
Macular Degeneration; Neoplasms; Prostatic Neoplasms, Castration-Resistant
Unknown
CGC-11047
×
Maximum Phase:
2
First Approval:
None
UNII:
HU43305R7O
Molecule Type:
Small molecule
Molecular Formula:
C14H32N4
Molecular Weight:
256.44
AlogP:
0.72
PSA:
48.12
HBD:
4.0
HBA:
#RotB:
14.0
Source:
REZATOMIDINE
2
Small molecule
Investigational
Unknown
Unknown
Cystitis, Interstitial; Diabetic Neuropathies; Fibromyalgia; Irritable Bowel Syndrome
Unknown
REZATOMIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
W5LMZ0RC8I
Molecule Type:
Small molecule
Molecular Formula:
C13H16N2S
Molecular Weight:
232.35
AlogP:
3.84
PSA:
31.58
HBD:
2.0
HBA:
#RotB:
2.0
Source:
GISADENAFIL
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive; Erectile Dysfunction; Prostatic Hyperplasia; Urinary Bladder, Overactive
Phosphodiesterase 5A inhibitor
GISADENAFIL
×
Maximum Phase:
2
First Approval:
None
UNII:
S6G4R7DI1C
Molecule Type:
Small molecule
Molecular Formula:
C23H33N7O5S
Molecular Weight:
519.63
AlogP:
1.12
PSA:
135.54
HBD:
1.0
HBA:
#RotB:
10.0
Source:
AV-101
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia; Depressive Disorder; Depressive Disorder, Major; Hypertension, Pulmonary
Glutamate [NMDA] receptor antagonist
AV-101
×
Maximum Phase:
2
First Approval:
None
UNII:
77XLH9L40B
Molecule Type:
Small molecule
Molecular Formula:
C10H11ClN2O3
Molecular Weight:
242.66
AlogP:
0.91
PSA:
106.41
HBD:
3.0
HBA:
#RotB:
4.0
Source:
FISPEMIFENE
2
Small molecule
Investigational
Unknown
Unknown
Erectile Dysfunction; Hypogonadism; Sexual Dysfunction, Physiological
Estrogen receptor modulator
FISPEMIFENE
×
Maximum Phase:
2
First Approval:
None
UNII:
3VZ2833V08
Molecule Type:
Small molecule
Molecular Formula:
C26H27ClO3
Molecular Weight:
422.95
AlogP:
5.66
PSA:
38.69
HBD:
1.0
HBA:
#RotB:
11.0
Source:
ORP-101
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome
Kappa opioid receptor antagonist
ORP-101
×
Maximum Phase:
2
First Approval:
None
UNII:
SE6KE496VO
Molecule Type:
Small molecule
Molecular Formula:
C60H84N2O8
Molecular Weight:
961.34
AlogP:
9.19
PSA:
102.32
HBD:
2.0
HBA:
#RotB:
13.0
Source:
ZALUNFIBAN
2
Small molecule
Investigational
Unknown
Unknown
Coronary Disease; ST Elevation Myocardial Infarction
Integrin alpha-IIb/beta-3 inhibitor
ZALUNFIBAN
×
Maximum Phase:
2
First Approval:
None
UNII:
5XQC91CO1F
Molecule Type:
Small molecule
Molecular Formula:
C16H18N8O2S
Molecular Weight:
386.44
AlogP:
-0.48
PSA:
130.54
HBD:
3.0
HBA:
#RotB:
4.0
Source:
RONICICLIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Small Cell Lung Carcinoma
Cyclin-dependent kinase inhibitor
RONICICLIB
×
Maximum Phase:
2
First Approval:
None
UNII:
0W9Q8U337A
Molecule Type:
Small molecule
Molecular Formula:
C18H21F3N4O3S
Molecular Weight:
430.45
AlogP:
3.96
PSA:
108.19
HBD:
3.0
HBA:
#RotB:
7.0
Source:
GSK-2245035
2
Small molecule
Investigational
Unknown
Unknown
Asthma
Toll-like receptor 7 agonist
GSK-2245035
×
Maximum Phase:
2
First Approval:
None
UNII:
5L3SX16QBQ
Molecule Type:
Small molecule
Molecular Formula:
C20H34N6O2
Molecular Weight:
390.53
AlogP:
2.93
PSA:
102.06
HBD:
2.0
HBA:
#RotB:
10.0
Source:
XL-281
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Neoplasms; Thyroid Neoplasms
Serine/threonine-protein kinase B-raf inhibitor
XL-281
×
Maximum Phase:
2
First Approval:
None
UNII:
DW2NWI3TFN
Molecule Type:
Small molecule
Molecular Formula:
C24H19ClN4O4
Molecular Weight:
462.89
AlogP:
4.56
PSA:
107.55
HBD:
3.0
HBA:
#RotB:
3.0
Source:
FARGLITAZAR
2
Small molecule
Investigational
Unknown
Unknown
Liver Cirrhosis
Peroxisome proliferator-activated receptor gamma agonist
FARGLITAZAR
×
Maximum Phase:
2
First Approval:
None
UNII:
3433GY7132
Molecule Type:
Small molecule
Molecular Formula:
C34H30N2O5
Molecular Weight:
546.62
AlogP:
6.61
PSA:
101.66
HBD:
2.0
HBA:
#RotB:
12.0
Source:
TILPISERTIB
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative
Mitogen-activated protein kinase kinase kinase 8 inhibitor
TILPISERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
A8Y5K4G762
Molecule Type:
Small molecule
Molecular Formula:
C33H33ClN8O
Molecular Weight:
593.13
AlogP:
6.37
PSA:
113.45
HBD:
2.0
HBA:
#RotB:
7.0
Source:
SGS742
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
SGS742
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GALLIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GALLIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
632XD903SP
Molecule Type:
Small molecule
Molecular Formula:
C7H6O5
Molecular Weight:
170.12
AlogP:
0.5
PSA:
97.99
HBD:
4.0
HBA:
#RotB:
1.0
Source:
[18F]FLUOROMISONIDAZOLE
2
Small molecule
Investigational
Unknown
Unknown
Brain Neoplasms; Carcinoma, Hepatocellular; Paraganglioma; Sarcoma; Carcinoma, Non-Small-Cell Lung
Unknown
[18F]FLUOROMISONIDAZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
8MSY49469G
Molecule Type:
Small molecule
Molecular Formula:
C6H8FN3O3
Molecular Weight:
188.15
AlogP:
0.12
PSA:
81.19
HBD:
1.0
HBA:
#RotB:
4.0
Source:
ODALASVIR
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Renal Insufficiency; Hepatitis C, Chronic
Nonstructural protein 5A inhibitor
ODALASVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
OVR52K7BDW
Molecule Type:
Small molecule
Molecular Formula:
C60H72N8O6
Molecular Weight:
1001.29
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
DEXTROMETHADONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DEXTROMETHADONE
×
Maximum Phase:
2
First Approval:
None
UNII:
S95RZH8AMH
Molecule Type:
Small molecule
Molecular Formula:
C21H27NO
Molecular Weight:
309.45
AlogP:
4.29
PSA:
20.31
HBD:
0.0
HBA:
#RotB:
7.0
Source:
LB80380
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Hepatitis B, Chronic
DNA disrupting agent
LB80380
×
Maximum Phase:
2
First Approval:
None
UNII:
S9I9P4J8IU
Molecule Type:
Small molecule
Molecular Formula:
C22H34N5O8P
Molecular Weight:
527.52
AlogP:
3.24
PSA:
166.98
HBD:
1.0
HBA:
#RotB:
11.0
Source:
SEPRANOLONE
2
Small molecule
Investigational
Unknown
Unknown
Migraine Disorders; Tourette Syndrome
Unknown
SEPRANOLONE
×
Maximum Phase:
2
First Approval:
None
UNII:
3P8Z6V53MU
Molecule Type:
Small molecule
Molecular Formula:
C21H34O2
Molecular Weight:
318.5
AlogP:
4.6
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
1.0
Source:
BLARCAMESINE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Parkinson Disease; Rett Syndrome
Unknown
BLARCAMESINE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
1M49V1PBPL
Molecule Type:
Small molecule
Molecular Formula:
C19H24ClNO
Molecular Weight:
317.86
AlogP:
3.53
PSA:
12.47
HBD:
0.0
HBA:
#RotB:
4.0
Source:
ARAMCHOL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ARAMCHOL
×
Maximum Phase:
2
First Approval:
None
UNII:
QE1Q24M65Y
Molecule Type:
Small molecule
Molecular Formula:
C44H79NO5
Molecular Weight:
702.12
AlogP:
10.61
PSA:
106.86
HBD:
4.0
HBA:
#RotB:
23.0
Source:
NEZULCITINIB
2
Small molecule
Investigational
Unknown
Unknown
Acute Lung Injury; COVID-19; Severe Acute Respiratory Syndrome
Janus Kinase (JAK) inhibitor
NEZULCITINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
CXA4I8AH6A
Molecule Type:
Small molecule
Molecular Formula:
C30H37N7O2
Molecular Weight:
527.67
AlogP:
3.8
PSA:
104.38
HBD:
3.0
HBA:
#RotB:
6.0
Source:
GLYCERYL TRIOLEATE
2
Small molecule
Investigational
Unknown
Unknown
Adrenoleukodystrophy
Unknown
GLYCERYL TRIOLEATE
×
Maximum Phase:
2
First Approval:
None
UNII:
O05EC62663
Molecule Type:
Small molecule
Molecular Formula:
C57H104O6
Molecular Weight:
885.45
AlogP:
18.1
PSA:
78.9
HBD:
0.0
HBA:
#RotB:
50.0
Source:
POLYSTYRENE SULFONATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
POLYSTYRENE SULFONATE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EPETIRIMOD
2
Small molecule
Investigational
Unknown
Unknown
Papillomavirus Infections
Unknown
EPETIRIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
9P5MH9F521
Molecule Type:
Small molecule
Molecular Formula:
C13H15N5
Molecular Weight:
241.3
AlogP:
2.22
PSA:
69.62
HBD:
1.0
HBA:
#RotB:
2.0
Source:
INDANTADOL
2
Small molecule
Investigational
Unknown
Unknown
Cough; Diabetic Neuropathies; Neuralgia; Pain
Glutamate [NMDA] receptor antagonist
INDANTADOL
×
Maximum Phase:
2
First Approval:
None
UNII:
Z3867B9SQP
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DARIGABAT
2
Small molecule
Investigational
Unknown
Unknown
Epilepsy; Anxiety Disorders; Epilepsy, Reflex; Low Back Pain; Panic Disorder; Seizures
GABA-A receptor; anion channel agonist
DARIGABAT
×
Maximum Phase:
2
First Approval:
None
UNII:
O9BP19HZ3Q
Molecule Type:
Small molecule
Molecular Formula:
C22H21FN4O3S
Molecular Weight:
440.5
AlogP:
4.12
PSA:
86.97
HBD:
0.0
HBA:
#RotB:
6.0
Source:
FLUZOPARIB
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Liver Diseases; Melanoma; Small Cell Lung Carcinoma; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Neoplasms; Nasopharyngeal Carcinoma; Neoplasms; Sarcoma; Triple Negative Breast Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Unknown
FLUZOPARIB
×
Maximum Phase:
2
First Approval:
None
UNII:
TWF0ML1CK8
Molecule Type:
Small molecule
Molecular Formula:
C22H16F4N6O2
Molecular Weight:
472.4
AlogP:
2.92
PSA:
96.77
HBD:
1.0
HBA:
#RotB:
3.0
Source:
GRAPIPRANT
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Osteoarthritis
Prostanoid EP4 receptor antagonist
GRAPIPRANT
×
Maximum Phase:
2
First Approval:
None
UNII:
J9F5ZPH7NB
Molecule Type:
Small molecule
Molecular Formula:
C26H29N5O3S
Molecular Weight:
491.62
AlogP:
4.14
PSA:
105.98
HBD:
2.0
HBA:
#RotB:
7.0
Source:
TEMPOL
2
Small molecule
Investigational
Unknown
Unknown
Anus Neoplasms; Cardiovascular Diseases; Alopecia; Glioblastoma; Prostatic Neoplasms, Castration-Resistant; Severe Acute Respiratory Syndrome
Unknown
TEMPOL
×
Maximum Phase:
2
First Approval:
None
UNII:
U78ZX2F65X
Molecule Type:
Small molecule
Molecular Formula:
C9H18NO2
Molecular Weight:
172.25
AlogP:
1.35
PSA:
43.37
HBD:
1.0
HBA:
#RotB:
0.0
Source:
GUSACITINIB
2
Small molecule
Investigational
Unknown
Unknown
Autoimmune Diseases; Hematologic Neoplasms; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Dermatitis; Dermatitis, Atopic
Janus Kinase (JAK) inhibitor
GUSACITINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
4801QYW816
Molecule Type:
Small molecule
Molecular Formula:
C24H28N8O2
Molecular Weight:
460.54
AlogP:
2.55
PSA:
134.06
HBD:
3.0
HBA:
#RotB:
5.0
Source:
LURTOTECAN
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Small Cell Lung Carcinoma
Unknown
LURTOTECAN
×
Maximum Phase:
2
First Approval:
None
UNII:
4J1L80T08I
Molecule Type:
Small molecule
Molecular Formula:
C28H30N4O6
Molecular Weight:
518.57
AlogP:
1.6
PSA:
106.36
HBD:
1.0
HBA:
#RotB:
3.0
Source:
1
2
…
110
111
112
113
114
115
116
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA